ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
예방 백신 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 830억 달러에서 2026년에는 903억 3,000만 달러에 이르고, CAGR 8.8%로 성장할 전망입니다. 지난 몇 년간의 성장은 전염병 근절 및 통제, 정부 주도의 예방접종 정책, 공중보건에 대한 인식 제고, 전 세계 예방접종 프로그램의 확립, 국제보건기구의 자금 지원 증가 등이 주요 요인으로 꼽힙니다.
예방 백신 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 1,312억 7,000만 달러에 이르고, CAGR은 9.8%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 차세대 백신 플랫폼 개발, 세계 인구 증가와 도시화 진행, 감염병 발생 대비 강화 노력 확대, 성인 예방접종 프로그램 확대, 백신 개발을 위한 민관 협력의 진전 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 국가 예방접종 프로그램 확대, 헬스케어 및 질병 관리에 대한 관심 증가, 소아 및 노인 백신 수요 증가, 복합백신 및 다가백신의 성장, 콜드체인 및 백신 보관 인프라 강화 등이 있습니다.
감염병의 확산은 향후 몇 년 동안 예방 백신 시장의 성장을 견인할 것으로 예측됩니다. 감염병은 세균, 바이러스, 곰팡이, 기생충 등 유해한 미생물에 의해 발생하며, 개인 간 또는 환경 노출을 통해 전파되는 질병을 말합니다. 감염성 질환의 확산 증가는 급속한 도시화, 국제 이동 증가, 항균제 내성 증가 등의 요인에 의해 촉진되고 있으며, 이 모든 요인들이 감염 확산의 가속화와 질병 관리의 어려움에 기여하고 있습니다. 예방백신은 감염이 발생하기 전에 면역체계를 활성화시켜 병원체를 식별하고 싸우도록 함으로써 질병 발생률과 전파율을 낮추는 등 감염병 관리에 중요한 역할을 합니다. 예를 들어, 스위스에 본부를 둔 정부 간 기구인 세계보건기구(WHO)에 따르면, 2023년 전 세계에서 새로 진단된 결핵(TB) 환자 수는 820만 명으로 2022년 750만 명에서 증가했습니다. 따라서 감염성 질환의 확산이 예방 백신 시장의 성장을 가속하고 있습니다.
예방백신 시장에서 사업을 전개하는 주요 기업들은 백신의 효능 향상, 안전성 프로파일 강화, 개발 및 생산 일정 가속화, 신흥 변종 감염병에 대한 광범위한 방어 제공, 차세대 mRNA 기술 플랫폼 등의 기술 혁신에 집중하고 있습니다. 첨단 mRNA 기술 플랫폼은 메신저 RNA를 이용하여 세포에 특정 항원생성을 지시하고 표적 면역반응을 유도합니다. 예를 들어, 2025년 3월 미국 생명공학 기업 Moderna Inc.는 차세대 코로나19 백신 'mRNA-1283(mNEXSPIKE)의 미국 식품의약국(FDA) 승인을 발표했습니다. 이 백신은 65세 이상의 성인과 12세에서 64세 사이의 CDC가 정의한 위험 요인을 하나 이상 가진 개인에게 접종하도록 승인되었습니다. mNEXSPIKE의 도입은 mRNA 백신 기술에서 큰 진전이며, 기존 제형에 비해 안정성이 향상되고 보관 요건이 간소화되었습니다. 이를 통해 특히 오지나 의료서비스가 부족한 지역에서 백신의 접근성과 유통을 개선할 수 있을 것으로 기대됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 TAM(Total Addressable Market) 규모
제9장 시장 세분화
제10장 지역별/국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업 및 혁신 기업
제38장 세계 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병(M&A)
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
LSH
영문 목차
영문목차
Preventive vaccines are biological products developed to protect individuals against infectious diseases by activating the immune system to identify and combat specific pathogens. They are given prior to exposure to disease-causing agents to prevent infection or lessen disease severity. Preventive vaccines are essential to public health efforts, as they help control and limit the spread of contagious illnesses.
The main types of preventive vaccines include live or attenuated vaccines, inactivated vaccines, toxoid vaccines, subunit vaccines, conjugate vaccines, DNA vaccines, and recombinant vector vaccines. Live or attenuated vaccines are produced using weakened forms of viruses or bacteria that trigger a strong and long-lasting immune response without causing illness. These vaccines target diseases such as pneumococcal infections, poliovirus, hepatitis, influenza, measles, rubella, and others. Distribution channels include hospitals, clinics, pharmacies, and other healthcare facilities, and the vaccines are administered across pediatric, adult, and geriatric age groups.
Tariffs have impacted the preventive vaccines market by increasing costs associated with imported raw materials, bioreactors, and cold chain equipment used in vaccine manufacturing and distribution. Live and recombinant vaccines are particularly affected due to their complex production requirements, with regions such as Asia-Pacific and Latin America facing higher cost pressures. These challenges can influence pricing and supply timelines; however, tariffs have also encouraged domestic vaccine manufacturing, capacity expansion, and regional self-sufficiency, supporting long-term market stability.
The preventive vaccines market research report is one of a series of new reports from The Business Research Company that provides preventive vaccines market statistics, including preventive vaccines industry global market size, regional shares, competitors with a preventive vaccines market share, detailed preventive vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the preventive vaccines industry. This preventive vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The preventive vaccines market size has grown strongly in recent years. It will grow from $83 billion in 2025 to $90.33 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to eradication and control of infectious diseases, government-led vaccination initiatives, rising public health awareness, establishment of global immunization programs, increased funding from international health organizations.
The preventive vaccines market size is expected to see strong growth in the next few years. It will grow to $131.27 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to development of next-generation vaccine platforms, rising global population and urbanization, increasing outbreak preparedness initiatives, expansion of adult immunization programs, growth in public-private partnerships in vaccine development. Major trends in the forecast period include expansion of national immunization programs, rising focus on preventive healthcare and disease control, increasing demand for pediatric and geriatric vaccination, growth in combination and multivalent vaccines, strengthening cold chain and vaccine storage infrastructure.
The rising prevalence of infectious diseases is anticipated to drive the growth of the preventive vaccines market in the coming years. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that can spread between individuals or through environmental exposure. The increase in infectious disease prevalence is fueled by factors including rapid urbanization, increased global travel, and the growing challenge of antimicrobial resistance, all of which contribute to faster transmission and more difficult disease control. Preventive vaccines play a critical role in managing infectious diseases by activating the immune system to identify and combat pathogens before infection occurs, thereby lowering disease incidence and transmission rates. For instance, in 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, the number of newly diagnosed tuberculosis (TB) cases globally reached 8.2 million in 2023, rising from 7.5 million cases in 2022. Therefore, the increasing prevalence of infectious diseases is fueling the growth of the preventive vaccines market.
Major companies operating in the preventive vaccines market are emphasizing technological advancements, such as next-generation mRNA technology platforms, to improve vaccine effectiveness, enhance safety profiles, accelerate development and production timelines, and provide broader protection against emerging infectious disease variants. Advanced mRNA technology platforms utilize messenger RNA to instruct cells to produce specific antigens, thereby generating a targeted immune response. For example, in March 2025, Moderna Inc., a US-based biotechnology company, announced U.S. Food and Drug Administration approval for mRNA-1283 (mNEXSPIKE), a next-generation COVID-19 vaccine. This vaccine is approved for adults aged 65 years and older, as well as individuals aged 12 to 64 with one or more CDC-defined risk factors. The introduction of mNEXSPIKE represents a major advancement in mRNA vaccine technology, offering improved stability and simpler storage requirements compared to earlier formulations, which is expected to enhance vaccine accessibility and distribution, particularly in remote and underserved regions.
In April 2024, European LifeCare Group, a UK-based vaccination services company, acquired PreventVaccins B.V. for an undisclosed amount. Through this acquisition, European LifeCare Group strengthened its European presence and expanded its vaccination services by enhancing operations in the Netherlands. PreventVaccins B.V. is a Netherlands-based biotechnology company focused on the development of preventive vaccines, particularly for infectious diseases.
Major companies operating in the preventive vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Sanofi Pasteur SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Takeda Pharmaceutical Company Limited, Moderna Inc., CSL Limited, Novavax Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., Bavarian Nordic A/S, Valneva SE, Panacea Biotec Ltd., Inovio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Afrigen Biologics and Vaccines (Pty) Ltd.
North America was the largest region in the preventive vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preventive vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the preventive vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The preventive vaccines market consists of sales of toxoid vaccines, plant-based vaccines, and combination vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Preventive Vaccines Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses preventive vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for preventive vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The preventive vaccines market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Type: Live Or Attenuated Vaccines; Inactivated Vaccines; Toxoid Vaccines; Subunit Vaccines; Conjugate Vaccines; DNA Vaccines; Recombinant Vector Vaccines
2) By Disease Type: Pneumococcal; Poliovirus; Hepatitis; Influenza; Measles; Rubella; Other Disease Types
3) By Age Group: Pediatric; Adult; Geriatric
4) By Distribution Channel: Hospitals; Clinics; Pharmacies; Other Distribution Channels
Subsegments:
1) By Live or Attenuated Vaccines: Measles, Mumps, and Rubella (MMR) Vaccine; Varicella (Chickenpox) Vaccine; Oral Polio Vaccine (OPV); Yellow Fever Vaccine; Rotavirus Vaccine; Bacillus Calmette-Guerin (BCG) Vaccine
2) By Inactivated Vaccines: Inactivated Poliovirus Vaccine (IPV); Hepatitis A Vaccine; Rabies Vaccine; Influenza (Inactivated) Vaccine; Japanese Encephalitis Vaccine
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.2.2 Rising Focus On Preventive Healthcare And Disease Control
4.2.3 Increasing Demand For Pediatric And Geriatric Vaccination
4.2.4 Growth In Combination And Multivalent Vaccines
4.2.5 Strengthening Cold Chain And Vaccine Storage Infrastructure
5. Preventive Vaccines Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Clinics
5.3 Public Health Organizations
5.4 Vaccination Centers
5.5 Pharmacies
6. Preventive Vaccines Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Preventive Vaccines Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Preventive Vaccines PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Preventive Vaccines Market Size, Comparisons And Growth Rate Analysis
7.3. Global Preventive Vaccines Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Preventive Vaccines Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Preventive Vaccines Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Preventive Vaccines Market Segmentation
9.1. Global Preventive Vaccines Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Live Or Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines
9.2. Global Preventive Vaccines Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Rubella, Other Disease Types
9.3. Global Preventive Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Pediatric, Adult, Geriatric
9.4. Global Preventive Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospitals, Clinics, Pharmacies, Other Distribution Channels
9.5. Global Preventive Vaccines Market, Sub-Segmentation Of Live Or Attenuated Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.6. Global Preventive Vaccines Market, Sub-Segmentation Of Inactivated Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Inactivated Poliovirus Vaccine (IPV), Hepatitis A Vaccine, Rabies Vaccine, Influenza (Inactivated) Vaccine, Japanese Encephalitis Vaccine
9.7. Global Preventive Vaccines Market, Sub-Segmentation Of Toxoid Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.8. Global Preventive Vaccines Market, Sub-Segmentation Of Subunit Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hepatitis B Vaccine, Human Papillomavirus (HPV) Vaccine, Pertussis (acellular) Vaccine, Influenza (recombinant protein) Vaccine
9.9. Global Preventive Vaccines Market, Sub-Segmentation Of Conjugate Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Pneumococcal Conjugate Vaccine (PCV), Haemophilus influenzae type b (Hib) Vaccine, Meningococcal Conjugate Vaccine
9.10. Global Preventive Vaccines Market, Sub-Segmentation Of DNA Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Zika Virus DNA Vaccine, Cytomegalovirus (CMV) DNA Vaccine, Infectious Disease DNA Vaccines
9.11. Global Preventive Vaccines Market, Sub-Segmentation Of Recombinant Vector Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Preventive Vaccines Market
12.1. China Preventive Vaccines Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Preventive Vaccines Market
13.1. India Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Preventive Vaccines Market
14.1. Japan Preventive Vaccines Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Preventive Vaccines Market
15.1. Australia Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Preventive Vaccines Market
16.1. Indonesia Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Preventive Vaccines Market
17.1. South Korea Preventive Vaccines Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. Taiwan Preventive Vaccines Market
18.1. Taiwan Preventive Vaccines Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Preventive Vaccines Market
19.1. South East Asia Preventive Vaccines Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Preventive Vaccines Market
20.1. Western Europe Preventive Vaccines Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Preventive Vaccines Market
21.1. UK Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Preventive Vaccines Market
22.1. Germany Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Preventive Vaccines Market
23.1. France Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Preventive Vaccines Market
24.1. Italy Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Preventive Vaccines Market
25.1. Spain Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Preventive Vaccines Market
26.1. Eastern Europe Preventive Vaccines Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Preventive Vaccines Market
27.1. Russia Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Preventive Vaccines Market
28.1. North America Preventive Vaccines Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Preventive Vaccines Market
29.1. USA Preventive Vaccines Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
30. Canada Preventive Vaccines Market
30.1. Canada Preventive Vaccines Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Preventive Vaccines Market
31.1. South America Preventive Vaccines Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Preventive Vaccines Market
32.1. Brazil Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Preventive Vaccines Market
33.1. Middle East Preventive Vaccines Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Preventive Vaccines Market
34.1. Africa Preventive Vaccines Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Preventive Vaccines Market Regulatory and Investment Landscape
36. Preventive Vaccines Market Competitive Landscape And Company Profiles
36.1. Preventive Vaccines Market Competitive Landscape And Market Share 2024
36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Preventive Vaccines Market - Company Scoring Matrix
36.2.1. Market Revenues
36.2.2. Product Innovation Score
36.2.3. Brand Recognition
36.3. Preventive Vaccines Market Company Profiles
36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
36.3.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
36.3.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
36.3.4. Sanofi Pasteur SA Overview, Products and Services, Strategy and Financial Analysis
36.3.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
37. Preventive Vaccines Market Other Major And Innovative Companies
GlaxoSmithKline plc (GSK), Takeda Pharmaceutical Company Limited, Moderna Inc., CSL Limited, Novavax Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., Bavarian Nordic A/S, Valneva SE, Panacea Biotec Ltd., Inovio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Afrigen Biologics and Vaccines (Pty) Ltd.
38. Global Preventive Vaccines Market Competitive Benchmarking And Dashboard
39. Key Mergers And Acquisitions In The Preventive Vaccines Market
40. Preventive Vaccines Market High Potential Countries, Segments and Strategies
40.1 Preventive Vaccines Market In 2030 - Countries Offering Most New Opportunities
40.2 Preventive Vaccines Market In 2030 - Segments Offering Most New Opportunities
40.3 Preventive Vaccines Market In 2030 - Growth Strategies
